Thor Halfdanarson, MD, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
Thor Halfdanarson, MD, medical oncologist at Mayo Clinic, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More